Oral Answers to Questions

Philippa Whitford Excerpts

Wednesday 25th January 2017 Commons Chamber

[The Prime Minister]

I recognise the issues that my hon. Friend has raised, and I can assure him that our commitment in relation to the northern parts of England, including Yorkshire, is absolutely clear. We want to back business growth right across the north, and we are backing the northern powerhouse to help the great cities and towns of the north to pool their strengths and take on the world. Yorkshire local enterprise partnerships have received an additional £156 million in Government funding this week, and we are spending a record £13 billion on transport across the north. As a result, there are more people in work in Yorkshire and the Humber than ever before, and the employment rate is at a record high. That is good news for people in the region and good news for our economy as a whole.

[Dr Philippa Whitford (Central Ayrshire) (SNP)]

Q5. The European Medicines Agency provides a single drug licensing system for 500 million people and results in the UK having drugs licensed six to 12 months ahead of countries like Canada and Australia. Yesterday, the Health Secretary stated that the UK will not be in the EMA, so can the Prime Minister confirm this and explain how she will prevent delayed drug access for UK patients?

[The Prime Minister]

There are a number of organisations that we are part of as members of the European Union. As part of the work that we are doing to look at the United Kingdom’s future after we leave the European Union, we are looking at the arrangements we can put in place in relation to those issues. The pharmaceutical industry in this country is a very important part of our economy, and the ability of people to access these new drugs is also important. I assure the hon. Lady that we are looking seriously at this and will ensure that we have the arrangements that we need.